BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer
BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer
复制标题
DOI：
10.1007/s00432-014-1704-5
复制
发表时间：
2014-09-01
影响因子：
3.6
通讯作者：
Ignatov, A.
中科院分区：
文献类型：
--
作者：
Ignatov, T.;Eggemann, H.;Ignatov, A.
为探讨BRCA 1基因启动子甲基化在散发性卵巢癌中的作用，检测了42例散发性卵巢癌患者BRCA 1基因启动子甲基化情况。在第二组137例卵巢癌患者中，BRCA 1启动子甲基化率分别为35.7%和33.6%。BRCA 1启动子甲基化与接受铂类-紫杉烷类辅助化疗的卵巢癌患者中位无进展生存期（PFS）显著增加相关（P = 0.008）。多变量分析显示，在调整其他预后因素后，BRCA 1启动子甲基化仍然是PFS的有利因素（HR 0.52; 95% CI 0.32-0.85，P = 0.009）。复发患者BRCA 1基因甲基化与中位PFS（18.5个月）显著相关，而非BRCA 1基因甲基化患者的中位PFS为12.8个月，BRCA 1基因甲基化可预测铂类紫杉烷类药物治疗的疗效。
The aim of the current study was to investigate the role of BRCA1 promoter methylation as predictive factor of response to platinum-taxane-based therapy in sporadic ovarian cancer.BRCA1 promoter methylation was analyzed in 42 sporadic epithelial ovarian cancers. The results were validated in a second cohort of 137 ovarian cancer patients.BRCA1 promoter methylation was observed in 35.7 % of patients in the first group and in 33.6 % in the second group. BRCA1 promoter methylation was associated with significant increase in median progression-free survival (PFS) of ovarian cancer patients receiving adjuvant platinum-taxane-based chemotherapy (P = 0.008). Multivariate analysis revealed that BRCA1 promoter methylation remains a favorable factor in regard to PFS (HR 0.52; 95 % CI 0.32-0.85, P = 0.009) after adjustment for other prognostic factors. Under the patients with recurrent disease, BRCA1 promoter methylation was associated with significant longer median PFS of 18.5 months in comparison with 12.8 months PFS for patients without BRCA1 promoter methylation.BRCA1 promoter methylation is predictive for better response to platinum-taxane-based therapy in EOC.